IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4477
Positioning
Market Dominance
Manufacturing
Medical Equipment
$132M
Pending
Detailed business profile pending verification.
Headcount
—
HQ Base
NATICK, Massachusetts
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ALUR ALLURION TECHNOLOGIES, INC. | 31 | 40 | 31 | 9 | - | - | 44.1% | -125.9% | 63.9% | -232.1% | -189.7% | -77.4% | 0.0% | - | $132M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ALLURION TECHNOLOGIES, INC. (ALUR) receives a "Avoid" rating with a composite score of 30.8/100. It ranks #4477 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Executive Directory Unavailable for ALUR
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
40
35
27
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for ALUR
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ALUR.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROIC -28.4% vs WACC 6.0% (spread -34.4%)
GM 64% vs sector 43%, OM -232% vs sector 1%
Capital turnover 0.10x, R&D intensity 55.4%
Rev growth -77%, 3yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags ALLURION TECHNOLOGIES, INC. with an Avoid rating, assigning a composite score of 30.8/100 and 1 out of 5 stars. Ranked #4477 of 7,333 stocks, ALUR falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ALUR's quality score of 40/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 44.1% (sector avg: -2.5%), gross margins of 63.9% (sector avg: 42.5%), net margins of -189.7% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 31/100, ALUR appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
ALLURION TECHNOLOGIES, INC.'s investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -77.4% vs. a sector average of 5.9% and a return on assets of -125.9% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ALLURION TECHNOLOGIES, INC. is experiencing notably weak momentum with a score of just 9/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -77.4% year-over-year, while a beta of 1.24 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
ALUR's stability score of 27/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.24. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 57/100 for ALUR suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.24), micro-cap liquidity risk. With a $132M market cap (micro-cap), ALLURION TECHNOLOGIES, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
ALLURION TECHNOLOGIES, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4477 of 7,333 overall (39th percentile). Key comparisons include ROE of 44.1% exceeding the -2.5% sector median and operating margins of -232.1% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ALUR currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (9) would have the largest impact on the composite score.
ROE 1877% BELOW SECTOR MEDIAN
Gross Margin 50% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 18094% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ALLURION TECHNOLOGIES, INC. (ALUR) as Avoid with a composite score of 30.8/100 at a current price of $1.30. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (40th percentile) and investment (35th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (9th percentile) and stability (27th percentile) tempers our overall conviction. We assign a No Moat rating (31/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ALLURION TECHNOLOGIES, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.8/100 places it at rank #4477 in our full 7,333-stock universe. At $132M in market capitalization, ALLURION TECHNOLOGIES, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -77% combined with momentum at the 9th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 64% (+21.4pp vs sector) narrow to operating margins of -232% (-233.4pp vs sector) and net margins of -189.7%, yielding a gross-to-net conversion rate of -297%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.30, ALLURION TECHNOLOGIES, INC. is trading at a premium to fundamental value. Our value factor score of 31/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/S of 0.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 64% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 44.1% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
The Avoid rating (composite 30.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -77% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -189.7% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to ALLURION TECHNOLOGIES, INC.. Key risk factors include current negative profitability (net margin -189.7%), below-average price stability (27th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -189.7%); below-average price stability (27th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 27th percentile and quality factor at the 40th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 64% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate ALLURION TECHNOLOGIES, INC.'s capital allocation as Poor. Key concerns include negative profitability, weak asset returns (ROA -125.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — ALLURION TECHNOLOGIES, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, ALLURION TECHNOLOGIES, INC. receives a Avoid rating with a composite score of 30.8/100 (rank #4477 of 7,333). Our quantitative framework assigns a No Moat (31/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on ALLURION TECHNOLOGIES, INC. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign ALLURION TECHNOLOGIES, INC. a meaningful economic moat, scoring 31/100 on our composite assessment. The ROIC-WACC spread of -34.4% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 11.8/20.
The strongest moat sources are margin superiority (11.8/20) and reinvestment efficiency (7/20). GM 64% vs sector 43%, OM -232% vs sector 1%. Capital turnover 0.10x, R&D intensity 55.4%. These pillars form the core of ALLURION TECHNOLOGIES, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (2.5/20) and economic value creation (2.7/20). Interest coverage N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ALLURION TECHNOLOGIES, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 64% providing a solid profitability foundation, declining revenues (-77%) that pressure the earnings outlook, returns on equity of 44.1% driving shareholder value creation. The margin cascade from 64% gross to -232% operating to -189.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 40th percentile.
The margin profile shows gross margins of 64%, operating margins of -232%, net margins of -189.7%. Return metrics include ROE of 44.1% and ROA of -125.9%. Relative to the Manufacturing sector, gross margins are 21.4 percentage points above the sector median of 43%, and ROE of 44.1% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of -77%. Overall balance sheet health is adequate for the current business environment.
Weak momentum (9th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Above 50MA
37.18%
Net New Highs
+51081

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03. Check This Out: Insiders Buying Walgreens And 2 Other Stocks Leading and Lagging Sectors Communication services shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares rose by just 0.1%. Top Headline Shares of RPM International Inc. (NYSE: RPM) fell more than 5% on Thursday after the company reported third-quarter FY24 results. Sales rose 0.4% Y/Y to $1.523 billion, slightly beating the consensus of $1.518 billion. Adjusted EPS of 52 cents exceeded the consensus of 46 cents. Equities Trading UP TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares shot up 59% to $2.0597. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Shares of Allurion Technologies Inc. (NASDAQ: ALUR) got a boost, surging 101% to $3.46 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock ...

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Allurion Technologies Inc. (NASDAQ: ALUR) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target. Tevogen Bio Holdings Inc. (NASDAQ: TVGN) shares climbed 40.6% to $3.58. Tevogen Bio, on Wednesday, appointed Tapan V Shah as Head of Investor Relations and Corporate Development. HWH International Inc. (NASDAQ: HWH) gained 38.8% to $2.1765. Candel Therapeutics, Inc. (NASDAQ: CADL) rose 36.3% to $2.2899 after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer. MacroGenics, Inc. (NASDAQ: MGNX) climbed 27.8% to $17.47. MacroGenics announced TAMARACK study data will not be presented at the ASCO Annual Meeting. E-Home Household Service Holdings Limited (NASDAQ: EJH) gained 27% to $2.22. Reliance Global Group, Inc. (NASDAQ: RELI) gained 24.6% to $0.46 after the company reported FY23 earnings. Simulations Plus, Inc. (NASDAQ: SLP) rose 22.5% to $47.12 after the company posted better-than-expected results for its second quarter. Vast Renewables Limited (NASDAQ: VSTE) gained 22.3% to $8.81. Sportsman's Warehouse Holdings, Inc. (NASDAQ: SPWH) gained 21.3% to $3.7950 following a narrower-than-expected quarterly loss. Gorilla Technology Group Inc. (NASDAQ: GRRR) jumped 19% to $0.8729 after the company reported a year-over-year increase in FY23 sales results. Levi Strauss & Co. (NYSE: LEVI) shares rose 18.3% to $22.10 after the company reported upbeat earnings ...

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ rose 0.85% to 16,411.43. The S&P 500 also rose, gaining, 0.67% to 5,246.15. Check This Out: Insiders Buying Walgreens And 2 Other Stocks Leading and Lagging Sectors Real estate shares jumped by 1.2% on Thursday. In trading on Thursday, energy shares rose by just 0.2%. Top Headline U.S. initial jobless claims rose by 11,000 from the previous week’s revised reading to 221,000 on March, the most in two months. Equities Trading UP TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares shot up 118% to $2.85. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Shares of Allurion Technologies Inc. (NASDAQ: ALUR) got a boost, surging 61% to $2.78 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a ...

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates of $258.41 million. ReNew Energy raised its FY24 adjusted EBITDA guidance to INR 62 billion - INR 66 billion. ReNew Energy Global gained 13.6% to $6.74 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares jumped 147.2% to $0.4179. Brüush received Nasdaq notification regarding minimum bid requirements. Cuentas Inc. (NASDAQ: CUEN) shares gained 59% to $1.5098 after reporting a narrower quarterly loss. Altamira Therapeutics Ltd. (NASDAQ: CYTO) jumped 52% to $0.4280. Altamira Therapeutics recently entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) gained 41.4% to $1.4000. Cardio Diagnostics Holdings announced the publication of its study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association. YPF Sociedad Anónima (NYSE: YPF) shares climbed 40.8% to $15.11. Javier Milei‘s victory in Argentina’s presidential election sparked a rally in Argentine ADRs trading on major U.S. stock exchanges. GD Culture Group Limited (NASDAQ: GDC) rose 26.8% to $4.3074. GD Culture Group unveiled its transformative and photorealistic AI-driven digital human technology on TikTok. Blue Star Foods Corp. (NASDAQ: BSFC) shares gained 26.8% to $0.1752 after jumping 18% on Friday. Blue Star Foods recently signed a 2-year bid award purchase agreement with Sysco Corporation. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) gained 25.3% to $4.2729. MIRA Pharmaceuticals announced exclusive licensing agreement for oral ketamine analog, Ketamir-2. Grupo Financiero Galicia S.A. (NASDAQ: GGAL) rose 25% to $15.63 after gaining 5% on Friday. Transportadora de Gas del Sur S.A. (NYSE: TGS) shares climbed 23.1% to $12.88 after gaining over 4% on Friday. Central Puerto S.A. (NYSE: CEPU) climbed 23.1% to $7.58. Pampa Energía S.A. (NYSE: PAM) gained 23% to $45.60. Transportadora de Gas del Sur S.A. (NYSE: TGS) rose 22.6% to $12.82 after ...